Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1116285.RA9JElnq1XDbgkUCQxjnCw1yj1jyf3UWknmkT3tIdSeDU130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1116285.RA9JElnq1XDbgkUCQxjnCw1yj1jyf3UWknmkT3tIdSeDU130_assertion type Assertion NP1116285.RA9JElnq1XDbgkUCQxjnCw1yj1jyf3UWknmkT3tIdSeDU130_head.
- NP1116285.RA9JElnq1XDbgkUCQxjnCw1yj1jyf3UWknmkT3tIdSeDU130_assertion description "[Class I phosphoinositide 3-kinases (PI3K) have been extensively studied in different models these last years and several isoforms are now promising drug targets to treat cancer and immune diseases.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1116285.RA9JElnq1XDbgkUCQxjnCw1yj1jyf3UWknmkT3tIdSeDU130_provenance.
- NP1116285.RA9JElnq1XDbgkUCQxjnCw1yj1jyf3UWknmkT3tIdSeDU130_assertion evidence source_evidence_literature NP1116285.RA9JElnq1XDbgkUCQxjnCw1yj1jyf3UWknmkT3tIdSeDU130_provenance.
- NP1116285.RA9JElnq1XDbgkUCQxjnCw1yj1jyf3UWknmkT3tIdSeDU130_assertion SIO_000772 24095650 NP1116285.RA9JElnq1XDbgkUCQxjnCw1yj1jyf3UWknmkT3tIdSeDU130_provenance.
- NP1116285.RA9JElnq1XDbgkUCQxjnCw1yj1jyf3UWknmkT3tIdSeDU130_assertion wasDerivedFrom befree-2016 NP1116285.RA9JElnq1XDbgkUCQxjnCw1yj1jyf3UWknmkT3tIdSeDU130_provenance.
- NP1116285.RA9JElnq1XDbgkUCQxjnCw1yj1jyf3UWknmkT3tIdSeDU130_assertion wasGeneratedBy ECO_0000203 NP1116285.RA9JElnq1XDbgkUCQxjnCw1yj1jyf3UWknmkT3tIdSeDU130_provenance.